Sandbox g19: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 51: | Line 51: | ||
* Pathogen-directed antimicrobial therapy | * Pathogen-directed antimicrobial therapy | ||
:* Bacteria | :* Bacteria | ||
::* Actinomyces | ::* '''Actinomyces''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Penicillin G]] 24 MU q4h | ::::* [[Penicillin G]] 24 MU q4h | ||
::* Bacteroides fragilis | ::* '''Bacteroides fragilis''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Metronidazole]] 30 mg/kg/day q6h | ::::* [[Metronidazole]] 30 mg/kg/day q6h | ||
::* Enterobacteriaceae | ::* '''Enterobacteriaceae''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Ceftriaxone]] 4 g/day q12h | ::::* [[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Ceftriaxone]] 4 g/day q12h | ||
::* Fusobacterium | ::* '''Fusobacterium''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Metronidazole]] 30 mg/kg/day q6h | ::::* [[Metronidazole]] 30 mg/kg/day q6h | ||
::* Haemophilus | ::* '''Haemophilus''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Ceftriaxone]] 4 g/day q12h | ::::* [[Cefotaxime]] 8–12 g/day q4–6h {{or}} [[Ceftriaxone]] 4 g/day q12h | ||
::* Listeria monocytogenes | ::* '''Listeria monocytogenes''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Ampicillin]] 12 g/day q4h {{or}} [[Penicillin G]] 24 MU q4h | ::::* [[Ampicillin]] 12 g/day q4h {{or}} [[Penicillin G]] 24 MU q4h | ||
::* Nocardia | ::* '''Nocardia''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[TMP-SMZ]] 10–20 mg/kg/day q6–12h {{or}} [[Sulfadiazine]] 4–6 g/day q6h | ::::* [[TMP-SMZ]] 10–20 mg/kg/day q6–12h {{or}} [[Sulfadiazine]] 4–6 g/day q6h | ||
::* Prevotella melaninogenica | ::* '''Prevotella melaninogenica''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Metronidazole]] 30 mg/kg/day q6h | ::::* [[Metronidazole]] 30 mg/kg/day q6h | ||
::* Pseudomonas aeruginosa | ::* '''Pseudomonas aeruginosa''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Ceftazidime]] 6 g/day q8h {{or}} [[Cefepime]] 6 g/day q8h | ::::* [[Ceftazidime]] 6 g/day q8h {{or}} [[Cefepime]] 6 g/day q8h | ||
::* | ::* '''Staphylococcus aureus, methicillin-susceptible''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Nafcillin]] 12 g/day q4h {{or}} [[Oxacillin]] 12 g/day q4h | ::::* [[Nafcillin]] 12 g/day q4h {{or}} [[Oxacillin]] 12 g/day q4h | ||
::* | ::* '''Staphylococcus aureus, methicillin-resistant''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Vancomycin]] 30–45 mg/kg/day q8–12h | ::::* [[Vancomycin]] 30–45 mg/kg/day q8–12h | ||
::* Streptococcus anginosus and other streptococci | ::* '''Streptococcus anginosus and other streptococci''' | ||
:::* Preferred regimen | :::* Preferred regimen | ||
::::* [[Penicillin G]] 24 MU q4h | ::::* [[Penicillin G]] 24 MU q4h | ||
Revision as of 05:14, 5 June 2015
Brain abscess
- Empiric antimicrobial therapy
- Brain abscess in otherwise healthy patients
- Preferred regimen
- Cefotaxime 8–12 g/day IV q4–6h OR Ceftriaxone 4 g/day IV q12h AND Metronidazole 30 mg/kg/day IV q6h
- Alternative regimen
- Meropenem 6 g/day IV q8h
- Brain abscess with comorbidities
- Otitis media, mastoiditis, or sinusitis
- Preferred regimen
- (Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h) AND Metronidazole 30 mg/kg/day q6h
- Dental infection
- Preferred regimen
- Penicillin G 24 MU q4h AND Metronidazole 30 mg/kg/day q6h
- Penetrating trauma or post-neurosurgy
- Preferred regimen
- (Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h) AND Vancomycin 30–45 mg/kg/day q8–12h
- Lung abscess, empyema, or bronchiectasis
- Preferred regimen
- Penicillin G 24 MU q4h AND Metronidazole 30 mg/kg/day q6h AND TMP-SMZ 10–20 mg/kg/day q6–12h
- Bacterial endocarditis
- Preferred regimen
- Vancomycin 30–45 mg/kg/day q8–12h AND Gentamicin 5 mg/kg/day IV q8h
- Congenital heart disease
- Preferred regimen
- Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h
- Transplant recipients
- Preferred regimen
- (Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h) AND Metronidazole 30 mg/kg/day q6h AND Voriconazole 8 mg/kg/day q12h AND (TMP-SMZ 10–20 mg/kg/day q6–12h OR Sulfadiazine 4–6 g/day q6h)
- Patients with HIV/AIDS
- Preferred regimen
- (Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h) AND Sulfadiazine 4–6 g/day q6h AND Pyrimethamine 25–100 mg/day qd
- Staphylococcus aureus coverage
- Preferred regimen
- Vancomycin 30–45 mg/kg/day q8–12h
- Mycobacterium tuberculosis coverage
- Preferred regimen
- Isoniazid 300 mg qd AND Rifampin 600 mg qd AND Pyrazinamide 15–30 mg qd AND Ethambutol 15 mg/kg/day qd
- Pathogen-directed antimicrobial therapy
- Bacteria
- Actinomyces
- Preferred regimen
- Penicillin G 24 MU q4h
- Bacteroides fragilis
- Preferred regimen
- Metronidazole 30 mg/kg/day q6h
- Enterobacteriaceae
- Preferred regimen
- Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h
- Fusobacterium
- Preferred regimen
- Metronidazole 30 mg/kg/day q6h
- Haemophilus
- Preferred regimen
- Cefotaxime 8–12 g/day q4–6h OR Ceftriaxone 4 g/day q12h
- Listeria monocytogenes
- Preferred regimen
- Ampicillin 12 g/day q4h OR Penicillin G 24 MU q4h
- Nocardia
- Preferred regimen
- TMP-SMZ 10–20 mg/kg/day q6–12h OR Sulfadiazine 4–6 g/day q6h
- Prevotella melaninogenica
- Preferred regimen
- Metronidazole 30 mg/kg/day q6h
- Pseudomonas aeruginosa
- Preferred regimen
- Ceftazidime 6 g/day q8h OR Cefepime 6 g/day q8h
- Staphylococcus aureus, methicillin-resistant
- Preferred regimen
- Vancomycin 30–45 mg/kg/day q8–12h
- Streptococcus anginosus and other streptococci
- Preferred regimen
- Penicillin G 24 MU q4h